The research will help ensure new treatments reflect the needs and preferences of patients and family members living with myeloma and other conditions.
Regenerative medical devices group Tissue Regenix has been granted a Human Tissue Authority (HTA) licence to import and distribute its portfolio of human tissue derived products from the US for use in the UK market.